IMVT · Immunovant, Inc.

Track IMVT — free

$44.37 +0.02 (+0.05%) At close · Aug 21

Market Cap

$9.17B

206.55M

Up next

Next earnings call

Nov 10, 2026 Est · unconfirmed · in 11 wks

FQ2-27 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 6, 2026

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Weak Quant / Vol High

Market backdrop VIX 15.1 · calm Equity put/call 0.58

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +50%

above

Price vs 50-day avg +13%

above

RSI (14) 70

neutral

MACD trend Positive

52-week position 98%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +13%

trailing

6-month return +60%

trailing

YTD return +75%

this year

Relative strength +48%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $39 › 200d $30 — 50d above 200d

Institutional flow Accumulating

+5% holders QoQ · +38 funds added

Insider flow Distributing

Net -$11.7M over 90 days · 100% sells

Short interest Falling

7.93% of float · ▼ -7.8% MoM · 18.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

227 holders — near 3-yr high, broad support

Squeeze score 67

elevated · 0–100

Fundamentals

Weak

EPS growth −1%

Y/Y

Free cash flow $-407.3M

Balance sheet $902.1M

net cash

Quant / Vol

risk profile

High

Volatility 61%

annualized · 1-yr

Max drawdown −17%

past year

ATR 3.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+50% Bullish

Price vs 50-day avg

+13% Bullish

RSI (14)

70 Neutral

MACD trend

Positive Bullish

52-week position

98% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $39 › 200d $30 — 50d above 200d

Institutional flow Accumulating

+5% holders QoQ · +38 funds added

Insider flow Distributing

Net -$11.7M over 90 days · 100% sells

Short interest Falling

7.93% of float · ▼ -7.8% MoM · 18.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

227 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $15 Now $44 · 98% Range high $45

vs 200-day avg +50% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Shares of common stock issued and outstanding	206,264,878	As of June 30, 2026	—
Adjusted general and administrative expenses (Non-GAAP) non-GAAP	50.23M	Year Ended March 31, 2026	—
Adjusted net loss (Non-GAAP) non-GAAP	-449.94M	Year Ended March 31, 2026	—
GAAP → non-GAAP reconciliation GAAP Net loss -$505.61M +$29.71M Research and development: Stock-based compensation +$26.01M General and administrative: Stock-based compensation -$62K Estimated income tax impact from adjustments = Adjusted net loss (Non-GAAP) -$449.94M
Adjusted research and development expenses (Non-GAAP) non-GAAP	426.95M	Year Ended March 31, 2026	—
Non-GAAP G&A expenses non-GAAP	$50.2M	fiscal year ended March 31, 2026	—

Non-GAAP net loss non-GAAP	$449.9M	fiscal year ended March 31, 2026	—

Non-GAAP R&D expenses non-GAAP	$426.9M	fiscal year ended March 31, 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
IMVT Immunovant, Inc. this stock	$9.17B	+74.5%	—	—	7.9%
VRTX Vertex Pharmaceuticals Inc / Ma	$136.93B	+20.9%	+46.2%	31.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$85.87B	+8.1%	+20.8%	20.7	3.3%
ARGX Argenx SE	$64.56B	+23.6%	—	—	2.1%
CSLLY Csl Ltd	$58.31B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

227

% held: 54.4%
Net QoQ: -1.0M sh
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

212

View

Short & Settlement

Short Interest Falling

Shares short

16.4M

Days to cover: 18.5d
Change: -1.4M sh

View

Short Volume

Short vol %

62%

As of: Aug 21, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $1.5K
As of: Jul 30, 2026

View

Off-Exchange

Off-exchange %

42.1%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$11.7M

Buyers / Sellers: 0 / 6

Buyers Sellers

View

Financials

Net income (FY)

$-505.6M

EPS diluted: $-2.77

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 7

View

Proposed Sales

Value

$384.6K

Shares: 10.0K
Filed: Jun 26, 2026

View

Exempt Offerings

Offering

$450.0M

Filed: Jan 21, 2025

View

Earnings & Events

Earnings Calls Upcoming

Next call

Sep 2, 2026

Last call: Aug 6, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
IMVT	+6.1%	+12.6%	+59.9%	+14.9%	+74.6%
SPY	-1.4%	+3.6%	+11.6%	+2.5%	+12.3%
vs SPY	+7.5%	+9.0%	+48.3%	+12.4%	+62.3%

Key facts CIK 1764013 CUSIP 45258J102 13F (30d) 217 filings 213 filers Visit website Investor relations

IMVT · Immunovant, Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance